TB-500 Studies: An Annotated Research Bibliography

The studies are organized by the type of biological model used, because model type is the single most important determinant of how a finding should be weighted. The overwhelming majority of the Tβ4/TB-500 literature consists of in-vitro (cell-culture) experiments and preclinical animal models (rats and mice). These establish mechanism and association in controlled systems but do not establish efficacy or safety in humans. A much smaller set of human clinical trials exists, almost entirely for topical or ophthalmic formulations of thymosin beta-4 (developed under names such as RGN-259), not for the injectable 'TB-500' material used in laboratory settings. Throughout, language such as 'was associated with' reflects the correlational and model-bound nature of the findings. Preclinical and clinical evidence are kept in separate buckets so the gap between them stays visible. None of the entries should be read as instructions for use in any organism.

These experiments use isolated cells to probe mechanism. They carry the least translational weight but are the foundation of the mechanistic story.

Malinda et al., 1997 (PMID 9194528, FASEB Journal). In a Boyden-chamber migration assay, thymosin beta-4 acted as a chemoattractant for human umbilical vein endothelial cells (HUVECs), stimulating directional migration four- to sixfold over medium-only controls. Evidence quality: in-vitro, single cell type; establishes a chemotactic effect on endothelial cells, not an in-vivo outcome.

These cell-level observations recur as the proposed mechanistic substrate (cell migration, actin dynamics) for the tissue-level associations reported in the animal models below.

This is the largest segment of the literature. All entries below are rodent (rat or mouse) models. They demonstrate associations within specific injury models and species; they do not establish human efficacy or safety, and effect sizes in rodents frequently do not translate.

Reviews synthesize primary literature but introduce no new experimental data; they are weighted as expert summary, not as evidence in themselves.

Morris et al., 2012 (PMID 23045978, Ann N Y Acad Sci). Reviews the authors' neurological models, reporting that thymosin beta-4 was associated with improved functional outcome in a rat embolic stroke model, a mouse multiple sclerosis model, and a rat traumatic brain injury model.

Kleinman et al., 2016 (PMID 27450738, Vitamins and Hormones). Reports that thymosin beta-4 increased the rate of dermal healing across multiple preclinical models, including diabetic and aged animals, and notes it was reported as safe and well tolerated in phase 2 clinical trials for pressure, stasis, and epidermolysis bullosa wounds.

Sosne et al., 2016 (PMID 27450739, Vitamins and Hormones). Reports that thymosin beta-4 (RGN-259) was associated with rapid corneal reepithelialization and reduced corneal inflammation across ophthalmic studies, supporting investigation as a corneal wound-healing agent.

Human clinical data for thymosin beta-4 are limited and concentrated in topical and ophthalmic formulations (RGN-259), not the injectable laboratory material. These are the highest-quality entries in this library and are reported here purely as research context describing what the trials studied.

Sosne et al., 2022 (PMID 36613994, Int J Mol Sci). In a human Phase III randomized, placebo-controlled, double-masked trial in neurotrophic keratopathy patients, complete healing of persistent epithelial defects occurred in 60% of RGN-259-treated subjects versus 12.5% of placebo at day 29 (p=0.0656, approaching but not reaching statistical significance), with no significant adverse effects and improvements in ocular comfort measures. Evidence quality: randomized controlled human trial; the primary comparison did not reach the conventional significance threshold, and the formulation studied was an ophthalmic solution. Additional clinical experience is summarized secondhand in the Kleinman 2016 review above (phase 2 dermal wound trials reported as safe and well tolerated).

Read as a whole, the TB-500 / thymosin beta-4 studies library is overwhelmingly preclinical: in-vitro endothelial assays and rodent models of dermal, ligament, cardiac, neurological, and hair-follicle injury, where the peptide was repeatedly associated with cell migration, matrix remodeling, angiogenesis, and improved functional or histological endpoints. The clinical record is narrow, formulation-specific (topical/ophthalmic RGN-259), and in its most rigorous published trial fell just short of statistical significance on its primary endpoint. That gap between consistent rodent signals and limited human confirmation is the central caveat for anyone surveying this literature.

Nothing on this page should be construed as evidence of benefit, safety, or efficacy in humans or animals, nor as dosing or administration guidance. The compound offered here is a reference material intended solely for in-vitro and laboratory research and is not for human or veterinary use. For physical characterization, see the data sheet and the storage and reconstitution guide; for a narrative overview and a plain-language findings summary, see the linked pillar and research-findings pages.